Director – Employment Counsel

PODD legal Deadline notice: important Insulet Deadline in Securities Fraud Class Action is approaching - investors notified to Contact BFA Law by August 31. A securities fraud class action lawsuit has been filed on behalf of Insulet investors after its stock plummeted over 6% because of misrepresentation about the safety of Insulet's Omnipod products. NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ:PODD) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Insulet, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/insulet-class-action-lawsuit. Key Details of the Insulet ($PODD) Class Action: * Lead Plaintiff Deadline: August 31, 2026 * Alleged Misconduct: Securities fraud relating to the safety of Insulet's Omnipod products * Largest Alleged Stock Drop: March 12, 2026 - 6.88% Stock Drop * Court: U.S. District Court for the District of Massachusetts * Take Action: Contact BFA Law to discuss your rights Insulet investors have until August 31, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Insulet securities. The class action is pending in the U.S. District Court for the District of Massachusetts. It is captioned Hu v. Insulet Corporation et al., No. 26-cv-13062. Why is Insulet Being Sued for Securities Fraud? Insulet is primarily engaged in the development, manufacture, and sale of insulin delivery systems for people with insulin-dependent diabetes through its Omnipod platform. The Omnipod platform includes: the Omnipod(R) 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH(R) Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Omnipod Eros"). Throughout the relevant period, Insulet misrepresented the safety of its Omnipod products as well as its ability to efficiently produce "medical grade quality at consumer electronic scale." In reality, certain of Insulet's products suffered from undisclosed manufacturing defects that put patient safety at risk. Why did Insulet's Stock Drop? On March 12, 2026, Insulet disclosed that a manufacturing issue with its Omnipod(R) 5 Pods caused a "tear in the internal tubing that delivers insulin" resulting in insulin being released inside the Pod "instead of being fully infused into the body as intended." Accordingly, Insulet "initiated a voluntary Medical Device Correction for specific lots of Omnipod(R) 5 Pods." This news caused the price of Insulet stock to drop $16.23 per share, or 6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84 per share on March 13, 2026. On May 26, 2026, Insulet announced another voluntary Medical Device Correction due to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and Omnipod Eros systems. It again indicated that the manufacturing issue resulted in a tear in the tubing which "could result in insulin under-delivery." This news caused the price of Insulet stock to drop $7.79 per share, or 5.07%, from a closing price of $218.11 per share on May 26, 2026, to $146.01 per share on May 27, 2026. What Can You Do? If you invested in Insulet, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa SMB Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Insulet Corporation has a consensus analyst price target of $360, implying 75% upside, with over 90% of analysts maintaining bullish ratings as of 6 April 2026. However, shares have fallen over 11% year-to-date and hit a 52-week low of $202.44 on 2 April, down more than 16% from a year earlier. The medical device company, which manufactures the Omnipod tubeless insulin pump, appointed Mike Panos as executive vice president and chief commercial officer on 30 March to strengthen commercial capabilities. CEO Ashley McEvoy cited significant growth opportunities driven by expanding global adoption of automated insulin delivery systems as the standard of care for both type 1 and type 2 diabetes.

MLSC partners highlight innovation and access at MassMEDIC Symposium and Gala. * April 2, 2026 As a proud sponsor of the 2026 MassMEDIC Medtech Impact Symposium and Gala, the Massachusetts Life Sciences Center (MLSC) joined partners and awardees from across the life sciences community to showcase the collaborations and investments driving meaningful progress for patients on a global scale. The Symposium brought together ecosystem leaders to explore how the medtech industry can deliver better outcomes while managing costs and sustaining innovation. In the afternoon, the Symposium shifted to three dynamic, concurrent panel tracks that examined the evolving landscape of healthcare delivery. Each panel featured practical, forward-looking dialogue focused on users, enabling technologies, and the accelerating shift in where care is delivered. MLSC-supported companies and partners played a key role throughout these discussions. Insulet Corporation, a crucial partner of the MLSC's Pathmaker program and a recipient of multiple Tax Incentive awards, participated in the panel, Everything, Everywhere, All the Time, which examined how healthcare systems balance quality, cost, and access in an increasingly complex environment. Panelists discussed how economic pressures, information gaps, and misaligned incentives continue to influence decision-making across the healthcare system. The MLSC has awarded Insulet with $16.3 million in tax incentives for the creation of 834 jobs. To date, the MLSC has invested $13.5 million in Pathmaker training organizations across Massachusetts, supporting more than 1,200 training opportunities and connecting graduates with 101 companies across the life sciences sector. Later in the afternoon, Gentuity, an industry partner of the MLSC's Bits to Bytes program, joined the panel, Talking Tech: Interventional Systems, where industry leaders shared perspectives on emerging trends and product innovation in interventional medical technologies. Through the Bits to Bytes program, the MLSC supports companies developing data-driven solutions that are advancing diagnosis and treatment. Over the past seven years, the program has awarded $27.6 million in capital funding to non-profit universities and academic medical centers who have partnered with companies like Gentuity, helping them bring cutting-edge technologies closer to patients. Rounding out the Symposium, MLSC COO Elizabeth Graham moderated a panel on assistive and autonomous technologies in clinical workflows, joined by leadership members of Johnson & Johnson MedTech - a longtime sponsor of the MLSC's Massachusetts Next Generation (MassNextGen) Initiative - and Robeauté, a company pioneering a new class of therapeutic microrobots. The discussion explored how tools such as surgical robotics, fully automated technologies, and critical care technologies are transforming care delivery, and examined the growing intersection of human expertise and automation. Since its founding in 2018, the MLSC's MassNextGen portfolio has grown to 39 companies, including 19 previous awardees that have raised seed or Series A financing. To date, MassNextGen companies have raised more than $401 million in follow-on funding. Reflecting the program's strong support for medical innovation, 28 percent of MassNextGen companies are developing novel technologies in the medical device space with the goal of improving patients' lives around the world. The day concluded with the Medtech Impact Gala, where the themes of the Symposium were reflected through powerful stories from patients and innovators. The evening celebrated the real-world impact of medical technology and recognized the individuals and organizations working to improve care around the world. The MLSC was proud to sponsor this event alongside several industry leaders and Tax Incentive awardees, including Insulet Corporation, Optikos, TransMedics, and ZOLL. Applications for several MLSC programs are now open, including Pathmaker, and both Impact Catalyst and MassNextGen with a deadline of June 12, 2026, at 1 p.m. EST. Announcements